Literature DB >> 404231

beta-Galactosidase deficiency in juvenile and adult patients. Report of six Japanese cases and review of literature.

Y Suzuki, N Nakamura, K Fukuoka, Y Shimada, M Uono.   

Abstract

Six juvenile and adult patients with progressive neurological diseases and beta-galactosidase deficiency were reported. Any diseases known to date were denied. These cases together with ten case reports in the literature were reviewed and were classified into three groups from clinical and biochemical points. Group 1 patients were characterized by progressive ataxia and myoclonus with gargoyl changes and macular cherry-red spots. In this syndrome beta-galactosidase activity seems to be secondarily affected by other biochemical defects. A group 2 patient showed similar neurological manifestations without gargoyle changes or macular cherry-red spots. Patients with these clinical features not associated with beta-galactosidase deficiency have also been described in the literature. Group 3 patients had progressive pyramidal and extrapyramidal disease without gargoyl changes or macular cherry-red spots. These cases may represent juvenile and adult type GM1-gangliosidosis. Accumulation of GM1 has not yet been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404231     DOI: 10.1007/bf00273261

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  28 in total

1.  FAMILIAL NEUROVISCERAL LIPIDOSIS. AN ANALYSIS OF EIGHT CASES OF A SYNDROME PREVIOUSLY REPORTED AS "HURLER-VARIANT," "PSEUDO-HURLER," AND "TAY-SACHS DISEASE WITH VISCERAL INVOLVEMENT".

Authors:  B H LANDING; F N SILVERMAN; J M CRAIG; M D JACOBY; M E LAHEY; D L CHADWICK
Journal:  Am J Dis Child       Date:  1964-11

2.  Juvenile GM1 gangliosidosis. Occurrence with absence of two beta-galactosidase components.

Authors:  J A Lowden; J W Callahan; M G Norman; M Thain; J S Prichard
Journal:  Arch Neurol       Date:  1974-09

3.  Late infantile systemic lipidosis. Major monosialogangliosidosis. Delineation of two types.

Authors:  D M Derry; J S Fawcett; F Andermann; L S Wolfe
Journal:  Neurology       Date:  1968-04       Impact factor: 9.910

4.  Macular cherry-red spot, myoclonic epilepsy, and neurovisceral storage in a 17-year-old girl.

Authors:  M L Goldstein; E H Kolodny; G G Gascon; F H Gilles
Journal:  Trans Am Neurol Assoc       Date:  1974

5.  [An autopsy case of a late form of familial amaurotic idiocy in comparison to the clinical and pathological findings on the two siblings with the same disease].

Authors:  Y Tokuda; K Harada; M Yamagami; H Shiraki
Journal:  Seishin Shinkeigaku Zasshi       Date:  1967-05

6.  Mycolonus epilepsy with cherry-red spot in adult: a peculiar form of mucopolysaccharidosis. (A clinical genetic, chemical and ultrastructural study).

Authors:  G C Guazzi; B Ghetti; F Barbieri; A Cecio
Journal:  Acta Neurol (Napoli)       Date:  1973 Sep-Oct

7.  Gmi-gangliosidosis. A variant with high activity of hepatic neutral beta-galactosidase.

Authors:  Y Suzuki; T Hayakawa; M Yazaki; Y Hiratani
Journal:  Eur J Pediatr       Date:  1976-06-08       Impact factor: 3.183

8.  beta-Galactosidase in mucopolysaccharidoses and mucolipidoses. Deficiency of GM1 beta-galactosidase in liver and leukocytes.

Authors:  Y Suzuki; K Fukuoka; J J Wey; S Handa
Journal:  Clin Chim Acta       Date:  1977-02-15       Impact factor: 3.786

9.  Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase.

Authors:  K Suzuki; Y Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

10.  Localized beta-galactosidase deficiency. Occurrence in cerebellar ataxia with myoclonus epilepsy and macular cherry-red spot--a new variant of GM1-gangliosidosis?

Authors:  A Yamamoto; S Adachi; S Kawamura; M Takahashi; T Kitani
Journal:  Arch Intern Med       Date:  1974-10
View more
  24 in total

Review 1.  Biochemistry and genetics of gangliosidoses.

Authors:  K Sandhoff; H Christomanou
Journal:  Hum Genet       Date:  1979       Impact factor: 4.132

Review 2.  Sialidosis: a review of human neuraminidase deficiency.

Authors:  J A Lowden; J S O'Brien
Journal:  Am J Hum Genet       Date:  1979-01       Impact factor: 11.025

3.  The lesions of an ovine lysosomal storage disease. Initial characterization.

Authors:  R D Murnane; D J Prieur; A J Ahern-Rindell; S M Parish; L L Collier
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

Review 4.  Screening for lysosomal disorders.

Authors:  K Ullrich
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

5.  The genetic defect in the various types of human beta-galactosidase deficiency.

Authors:  H L Hoeksema; J De Wit; A Westerveld
Journal:  Hum Genet       Date:  1980-02       Impact factor: 4.132

6.  GM1-gangliosidosis: accumulation of ganglioside GM1 in cultured skin fibroblasts and correlation with clinical types.

Authors:  Y Suzuki; N Nakamura; K Fukuoka
Journal:  Hum Genet       Date:  1978-08-31       Impact factor: 4.132

7.  The simple detection of neuraminic acid-containing urinary oligosaccharides in patients with glycoprotein storage diseases.

Authors:  A C Sewell
Journal:  J Inherit Metab Dis       Date:  1983       Impact factor: 4.982

8.  Type 3 GM1 gangliosidosis: clinical and neuroradiological findings in an 11-year-old girl.

Authors:  R Tanaka; T Momoi; A Yoshida; M Okumura; S Yamakura; Y Takasaki; T Kiyomasu; C Yamanaka
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

9.  Human beta-galactosidase gene mutations in GM1-gangliosidosis: a common mutation among Japanese adult/chronic cases.

Authors:  K Yoshida; A Oshima; M Shimmoto; Y Fukuhara; H Sakuraba; N Yanagisawa; Y Suzuki
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

10.  A severe infantile sialidosis (beta-galactosidase-alpha-neuraminidase deficiency) mimicking GM1-gangliosidosis type 1.

Authors:  S Okada; H Sugino; T Kato; T Yutaka; M Koike; T Dezawa; T Yamano; H Yabuuchi
Journal:  Eur J Pediatr       Date:  1983-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.